Cryogenic Ogs Limited

As of March 31, 2026, Cryogenic Ogs Limited carries a market capitalization of 2.28B, placing it among publicly traded companies globally. Its enterprise value stands at 2.04B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Cryogenic Ogs Limited has 14.28M shares outstanding.

As of March 31, 2026, Cryogenic Ogs Limited trades at a trailing price-to-earnings ratio of 20.81. The price-to-sales ratio is 5.19, and the price-to-book ratio stands at 4.18.

As of March 31, 2026, Cryogenic Ogs Limited trades at an EV/EBITDA multiple of 16.23 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.00 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 17.01 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Cryogenic Ogs Limited trades at an EV/FCF ratio of 39.92, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 2.04B versus a market cap of 2.28B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Cryogenic Ogs Limited maintains a current ratio of 13.30, meaning it holds 13.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 15.09, indicating elevated leverage, while an interest coverage ratio of 112.22 demonstrates strong ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Cryogenic Ogs Limited posted a return on equity (ROE) of 24.35, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 19.65 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 20.25, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 22.35, useful for judging operating efficiency across full business cycles. The company generates approximately 9.72M in revenue per employee across its workforce of 42.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.14 indicates how many times Cryogenic Ogs Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Cryogenic Ogs Limited recorded 33.09M in income tax expense. That works out to an effective tax rate of 24.53, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 134.92M, leaving 101.83M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Cryogenic Ogs Limited's stock has gained approximately 79.10% over the past 52 weeks. The 50-day moving average sits at 394.50, while the 200-day moving average is 258.82.

Over the twelve months ended March 31, 2026, Cryogenic Ogs Limited generated 408.22M in revenue and converted that into 101.83M in net income, yielding earnings per share of 7.69. EBITDA reached 125.69M, while operating income came in at 107.52M.

As of March 31, 2026, Cryogenic Ogs Limited holds 327.82M in cash and equivalents against 82.46M in total debt, resulting in a net debt position of -245.36M. Total book value stands at 546.52M, with working capital of 430.05M providing operational flexibility.

Cryogenic Ogs Limited produced 79.86M in operating cash flow over the twelve months ended March 31, 2026. After subtracting -29.62M in capital expenditures, free cash flow totaled 50.24M - equivalent to 3.79 per share.

Over the twelve months ended March 31, 2026, Cryogenic Ogs Limited posted a gross margin of 47.03, reflecting its pricing power and cost economics. The operating margin of 26.34 and net profit margin of 24.94 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield stands at 2.37, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -6.73, meaning Cryogenic Ogs Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.